OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on:
- DNA, RNA, and immune-based targeting
- The truth behind standard protocols
- What most doctors miss in treatment planning
- Stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
How Precision Medicine is Changing Cancer Forever
Exciting advancements in cancer treatment are showing promising results. A new study reveals a significant improvement in "quality of life" for stage 4 cancer patients. The new "treatment" also had fewer "side effects". This "cancer research" could give hope to those experiencing severe "cancer symptoms". Visit our "cancer center" for more information. envita.com
What if cancer treatment didn’t have to come with hair loss, exhaustion, and hopeless odds?
In this groundbreaking episode, Dr. Dino Prato shares how precision oncology is changing the game — with a 2024 peer-reviewed study* that found 72% of late-stage cancer patients treated with Envita’s personalized protocols experienced response or disease stability—35x higher than response rates reported for conventional palliative chemotherapy.
*View the research paper here:
https://www.scirp.org/journal/paperinformation?paperid=132493
🚀 Discover how Envita’s “N of 1” personalized approach uses over 1,000 data points to:
- Customize treatment for your DNA, RNA, immune profile & more
- Avoid overtreatment, reduce side effects, and improve outcomes
- Combine the best of integrative & conventional therapies, guided by data
Learn why one-size-fits-all cancer care is outdated — and how a new model is bringing health, and healing to patients who had no more options.
📊 Backed by real clinical results, advanced molecular targeting, and 25 years of innovation.
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493